HISA Appoints Bethany Erb To Director of Public Affairs

With over 18 years experience in government affairs and stakeholder engagement, Bethany Erb has been appointed to serve as Director of Public Affairs at the Horseracing Integrity and Safety Authority (HISA), the organization announced via press release Monday.

In the position, Erb will manage HISA's engagement with policymakers and other stakeholders in Washington, D.C. and around the country, which includes representatives from the Federal Trade Commission (FTC) as well as the various advocacy groups inside and outside of the industry. Erb's prior positions include within the U.S. Department of Agriculture, Congressional Sportsmen's Foundation, and the Land Trust Alliance as well as two appointments to the Hunting and Wildlife Conservation Council.

“I deeply respect the important work HISA is doing to protect equine athletes, jockeys, and the future of the sport,” said Erb. “Horses and equestrian sports have been an integral part of my life since childhood and I am excited to be part of this organization and help further its mission.”

HISA CEO Lisa Lazarus praised the appointment of Erb, calling her experience with large-scale and local advocacy groups an 'excellent choice' for the position.

“Bethany's experience on Capitol Hill and with leading national-level and grassroots advocacy efforts make her an excellent choice for this role; we are confident that her skills will be invaluable in advancing HISA's mission. She shares HISA's core values and unwavering commitment to the advancement of Thoroughbred racing, and we are thrilled to welcome her to the team.”

The post HISA Appoints Bethany Erb To Director of Public Affairs appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Letter To The Editor: Racing Surfaces And Testing

by Dr. Mick Peterson and Dr. Wayne McIlwraith

This year marks 15 years since the Racing Surfaces Testing Lab (RSTL) was founded by an engineering faculty member at the University of Maine and an orthopedic surgeon from Colorado State University. The non-commercial material testing lab emerged out of the 2006 Grayson-Jockey Club Welfare and Safety of the Racehorse Summit at the urging of Dennis Moore of Hollywood Park and Dan Fick of The Jockey Club. Initially located in one stall of a two-car detached garage in Orono, Maine, the independent non-profit was made possible by donations from The Jockey Club, National Thoroughbred Racing Association, Churchill Downs Inc., The New York Racing Association, California Association of Racing Fairs and Oak Tree Foundation.

The RSTL in 2023 has little in common with that modest start. Now located in Lexington, Kentucky, the RSTL is in a 3,400-square-foot building on a 1/4-acre lot. The fenced lot is filled with vans and trailers that performed more than 70 pre-meet inspections at 53 racetracks in 2023. The lab no longer just performs standard tests but develops tests in collaboration with the University of Kentucky and racetrack operators, researchers, and graduate students from Europe, Latin America, and Australia. Fifteen years ago, surface standards for horse racing in the United States lagged behind other racing jurisdictions and sports. Today, thanks to a combination of federal legislation and a unique gift, horse racing in the United States has the potential to become an international model for safety and consistency across sport surfaces.

The beginning of the shift started with a 2019 gift from The Jockey Club which enabled the RSTL to take over existing on-site testing and the maintenance database. The single set of equipment previously available for pre-meet inspection had been based in Maine and later in Lexington to serve all racetracks in the United States. The gift provided funding for equipment to be located in Lexington as well as on the West Coast.

With this equipment, the RSTL could perform pre-meet testing at racetracks across the United States and respond quickly if concerns arose. Laboratory material testing was modernized with new equipment, which allowed critical testing to be performed in less than an hour instead of over several days. The existing database was replaced by a new system hosted by The Jockey Club, which started the RSTL on a path to more comprehensive data storage and provided a modern interface for the racetracks to enter maintenance data. The timing could not have been more auspicious. Demand was poised to far outstrip the testing capabilities that existed prior to receiving the gift from The Jockey Club.

When the HISA Safety Regulations went into effect in July 2022, pre-meet inspection, material testing and daily measurements were required at all covered racetracks. As a result of these regulations, the Maintenance Quality System protocols developed over the previous decade had become more than suggestions followed by a few of the most progressive racetracks. Using the new equipment, pre-meet inspections were immediately implemented by the RSTL for HISA. Today, after only one and a half years, test data is available from all covered racetracks. Updated information infrastructure from The Jockey Club forms the backbone of a system that feeds data to HISA in real time. Epidemiological models of horse injuries can now begin to include quantitative racetrack surface data.

Work remains. Dirt, turf and synthetic racetrack surfaces need continuous improvement. Complete daily monitoring of the tracks exists at only a few racetracks. Real-time race surface data is needed by superintendents and researchers. However, the data infrastructure and regulatory framework is in place. New information can be fed to racetrack maintenance personnel. The commitment of the RSTL is unchanged. The design of equipment and testing protocols are all publicly available and subject to peer review. Data from the tracks is widely shared among other racetracks. No other racing jurisdiction and very few other sports have combined research with transparency to build surfaces that are consistent, from day to day, and throughout the United States and Canada.

Michael “Mick” Peterson, Ph.D. is the Director of the Racetrack Safety Program and Professor of Biosystems and Agricultural Engineering at the University of Kentucky. He is also the Executive Director and a co-founder of the Racing Surfaces Testing Laboratory. Wayne McIlwraith is the founding director of the Orthopaedic Research Center, a University Distinguished Professor in orthopaedics and holds the Barbara Cox Anthony University Chair in Orthopaedic Research at Colorado State University.

The post Letter To The Editor: Racing Surfaces And Testing appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

HISA To Fund Three Scientific Studies On The Use of Furosemide

Following a recommendation from its Furosemide Advisory Committee (FAC), the Horseracing Integrity and Safety Authority's Board of Directors approved $773,500 in grant funding for three scientific studies on the use of furosemide (also known as “Lasix”) to be conducted over the next two years by the Nationwide Children's Hospital, the University of Florida College of Veterinary Medicine and Washington State University, HISA said in a Wednesday release.

The studies will examine the 48-hour period before the start of a Covered Horserace, including the effects of furosemide on equine health and the integrity of competition. Researchers will be required to present final reports on their findings to the FAC on or before Jan. 31, 2026.

“The Furosemide Advisory Committee is grateful to the expert researchers who responded to our request for proposals and look forward to partnering with Nationwide Children's Hospital, the University of Florida College of Veterinary Medicine and Washington State University on this important research,” said FAC Chairman Dr. Scott Palmer, VMD. “The lifelong health and well-being of Thoroughbreds is our top priority. This work will help ensure we have policies in place to safeguard these remarkable animals and the integrity of the sport.”

Under the Horseracing Integrity and Safety Act, HISA is required to fund scientific research on the topic of furosemide to inform the FAC's future recommendations to the HISA Board on whether and how to amend their existing furosemide regulations.

A request for proposals was issued by HISA in August 2023. Out of those submitted, the following were recommended by the FAC and approved:

Examining Associations Between Furosemide Treatment & Racehorse Health and Welfare

Principal Investigator: Amanda Waller, Bsc, PhD, Research Scientist, Center for Clinical and Translational Research, Nationwide Children's Hospital
This study will examine the effects of race day furosemide treatment on the health and welfare of Thoroughbreds as well as their long-term racing performance. An analysis will be conducted to assess the association between pre-race furosemide administration and fatal injury, while also comparing the performance metrics–including lifetime earnings, career length, lifetime starts, starts per year, placings and average speed figures–of horses that raced exclusively on furosemide as 2-year-olds and horses that did not receive furosemide as juveniles.

 

Effects of Repeated Furosemide Administration on Electrolyte Homeostasis and Bone Density in Healthy Adult Exercising Thoroughbreds

Principal Investigator: SallyAnne L. DeNotta, DVM, PhD, DACVIM., Clinical Assistant Professor, Large Animal Medicine, University of Florida College of Veterinary Medicine
This study will examine the effects of repeated furosemide administration on electrolyte homeostasis, parathyroid response and urinary electrolyte excretion in exercising adult Thoroughbreds. The study will also examine the effects of repeated administration on bone density and strength using minimally invasive methods of measurement, including DEXA scan and OsteoProbe.

 

Does Pre-Race Administration of Furosemide to Thoroughbred Racehorses Prolong Their Racing Careers?

Principal Investigator: Warwick Bayly, BVSc, PhD, DACVIM, Professor, Department of Veterinary Clinical Sciences, Washington State University
This study will examine the impact of severe exercise-induced pulmonary hemorrhage (EIPH) on horses' careers and the health of the racing industry more broadly. In doing so, the study will assess whether regular furosemide treatment is associated with more career starts and greater longevity and the impact of banning furosemide for 2-year-olds on the duration of their careers and number of lifetime starts. The study will also seek to determine the extent to which severe EIPH impacts the number of subsequent starts, the periods between them and, when applicable, the time between the diagnosis of severe EIPH and retirement.

The post HISA To Fund Three Scientific Studies On The Use of Furosemide appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Facing A Two-Year Suspension For Clenbuterol, Trainer Jeffrey Englehart Says They’ve Got The Wrong Guy

On the surface, the case against trainer Jeffrey Englehart seems pretty cut and dried. He had a horse test positive for Clenbuterol, the bronchodilator that is on the Horseracing Integrity and Welfare Unit's (HIWU) list of banned substances. Trainers found using banned substances can be suspended for up to two years. But Englehart, who races at the NYRA tracks and at Finger Lakes, is adamant that he never gave the drug to the horse in question.

“We don't use Clenbuterol. Period,” Englehart said.

So is there more to this story? Dig a little deeper and you might conclude that there is. To Englehart, it's not about the fact that the horse tested positive. He doesn't dispute that finding. But when was the horse given Clenbuterol and by whom? He hopes the answers to those questions will clear his name and lead to HIWU dropping the case against him.

The horse that tested positive for Clenbuterol was an unnamed 2-year-old by Classic Empire out of Fast Heart. Englehart bought the horse on behalf of owner Marcello Rosa for $14,000 at the OBS auction June 15. The horse broke down while training and had to be euthanized at Finger Lakes Nov. 21.

Englehart's problems were just beginning.

HIWU performed a battery of tests on the deceased horse, including blood, urine and hair. The blood and urine tests were negative. According to Rick Arthur, former equine medical director for the California Horse Racing Board, a standard dose of Clenbuterol will typically be detectable in the blood for about three to four days after administration. For urine, the detection window would typically be between 10 to 17 days after administration.

But HIWU also performed a hair test, which revealed the presence of Clenbuterol. Englehart claims that hair tests can show the presence of the substance for up to a year after it was given to a horse. According to Arthur, Clenbuterol can be found in hair samples for at least six months after the drug was administered.

Dr. Rick Arthur | Horsephotos

“We've certainly seen Clenbuterol in hair up to six months,” said Arthur. “It could probably stay longer, we just haven't tried to look at it. We did a lot of hair testing for Clenbuterol in Quarter Horses at Los Alamitos. Trainers have contended that horses past six months have tested positive.”

After learning about how long after administration Clenbuterol can be found in a hair sample, Englehart started to do the math. The horse broke down exactly five months and six days after the purchase at OBS. That means, Englehart contends, that it is entirely possible that someone gave the horse the drug before he purchased it and that he could be suspended for something someone else did.

“(HIWU) say it's in the horse's system, so you are guilty,” said Englehart, who is still training while awaiting he results of the split sample test done on the Classic Empire colt. “It doesn't matter to them that it can stay in the system for up to a year and I only had the horse for less than six months. That's completely unfair. They are trying to upend my life.”

The unraced colt was sold for $4,000 at the Fasig-Tipton Kentucky October Yearling Sale Oct. 26, 2022. The consignor was Vinery Sales and the purchaser was Juan Centeno. The latter, who sells under the name of All Dreams Equine, turned around and put the horse in OBS June. It was one of five horses who successfully went through the ring, including a horse named She She's Shadow (Bucchero), who was also purchased by Englehart.

When asked if She She's Shadow was tested and what the results were, Alexa Ravit, the director of communications & outreach for HIWU, said in an email response to the TDN: “HIWU cannot comment on what horses have been sampled or their subsequent test results beyond what is published on our website in accordance with the ADMC Program's public disclosure requirements.”

Englehart's theory is that Centeno gave the Clenbuterol to the horse in hopes that it would help the colt have a fast pre-sale workout. The horse put in a two-furlong breeze in :22.

“I don't know the gentleman from All Dreams Equine,” Englehart said. “I just know it had to be him because I know it wasn't me.”

Centeno did not respond to emails, text messages and phone calls from the TDN requesting a comment.

Englehart alleged that Clenbuterol use is “rampant” at the 2-year-old sales.

“This horse was probably training on (Clenbuterol) right up to day he sold,” Englehart said. “It's very well known that Clenbuterol use is rampant at sales. Every trainer knows that. I think if they did a hair test on every horse 70 to 80 percent would be positive for Clenbuterol.”

Under OBS's conditions of sale, no medication may be administered within 24 hours of a horse's under-tack performance. Several specific medications may not be administered on the sales grounds or present in a test sample, including Clenbuterol. OBS tests around 10-15% of the horses who are going to sell, but does not do hair-sample tests, just blood and urine. This colt was not one of those randomly tested in June, the sales company said.

Tom Ventura | Patty Wolfe

When asked to elaborate on the sales company's rules regarding Clenbuterol, OBS President Tom Ventura said every step possible is taken to make sure that no horse in the sale has been given that particular drug.

“With our policy for bronchodilators, including Clenbuterol, we were ahead of the racing curve, because the sales companies have the ability within the conditions of sale to put policies in place maybe a little quicker than jumping through the regulatory hoops that are required at the racetracks,” Ventura said. “OBS, in October of 2019, prohibited bronchodilators. Period. In any animal at any level, in any type of sale.

“Since the very beginning of the tests, I think we had two early on who tested positive and didn't go through the ring, so two positives that we have had for Clenbuterol in four years. I know there weren't any in the last year. We test them as they're coming off the racetrack, and then the buyers have the right to test when they sign the sales ticket. We haven't had any returns for Clenbuterol from those tests.”

In limbo while awaiting the results of the split sample, Englehart has continued his own investigation. He believes the answer to his problems may lie in what is called a segmented drug test, which can provide a time line so far as when a drug was used.

According to the website cellmark.co.uk, by segmenting head hair samples into monthly one-centimeter sections, a month-by-month historic profile of drug use can be obtained. That goes for humans and horses.

If the segmented test shows that the Clenbuterol was administered prior to the day when Englehart bought the horse, it would seem to prove his point that someone else must have given the drug to the horse and lead, he believes, to him being exonerated.

Englehart has sent a hair sample off to the lab at Texas A&M and asked it to do a segmented test.

“I'm just hoping they look at the science and I don't have to do the suspension,” he said.

The problem is that he doesn't know if HIWU will also do a segmented test. Will they? Have they? HIWU won't say.

“HIWU cannot publicly comment on the specific facts of pending cases, including whether segmented analysis was conducted on samples taken from specific horses,” Ravit said in another email.

Finger Lakes | Sarah Andrew

That's not reassuring to Englehart, who points out that the problem extends beyond sales. Horses often change hands, whether being bought at auction, being claimed or being privately purchased, and if they test positive for Clenbuterol through hair tests it would be unfair to automatically penalize the person who had the horse at the time it tested positive.

“The average horseman who bought a horse or has a horse in their possession for only a short period of time, they can't be dropping the hammer on them when something can still show up in these tests after a year,” Englehart said. “You have to know when the horse was given the Clenbuterol.”

We posed this question to HIWU: “Could a horse be given Clenbuterol by someone prior to being transferred to a new trainer and test positive? That would mean the current trainer would be getting penalized for something someone else did. Is this a plausible scenario?”

Ravit's response did not answer that question.

“HIWU cannot comment on the specific questions regarding Englehart's pending case, including the samples collected and type of testing conducted on Fast Heart 2021, the expected timeline to receive the B Sample results, and the plausibility of his defense,” she wrote. “Additionally, HIWU cannot speculate on the adjudication of the hypothetical case you described, for the outcome would depend on the specific facts of the case.”

Englehart is worried that he is running short on time. Once the results of split sample are in and as long as it also shows the presence of Clenbuterol, he will be facing what could be an immediate suspension that can last as long as two years.

“I'm just hoping that the tests comes back and vindicates me,” he said. “I will fight this as hard as you can and take this as far as necessary. I'm ready to take it to the courts. Meanwhile, this has been a nightmare for me.”

Dan Ross contributed to this story.

The post Facing A Two-Year Suspension For Clenbuterol, Trainer Jeffrey Englehart Says They’ve Got The Wrong Guy appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights